Organization and Basis of Presentation - Narrative (Detail)				12 Months Ended
	Jul. 01, 2015 shares	Oct. 24, 2014 USD ($)	May. 16, 2014 USD ($)	Dec. 31, 2015 USD ($) product shares	Dec. 31, 2014 USD ($) shares	Dec. 31, 2013 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of product candidates | product				2
Reverse stock split conversion ratio	0.125
Common stock, shares authorized | shares	50,000,000			50,000,000	50,000,000
Business Acquisition [Line Items]
Proceeds from sale of business				$ 82,984,000	$ 89,624,000	$ 0
Brabant Pharma Limited [Member]
Business Acquisition [Line Items]
Aggregate amount of contingent liabilities		$ 95,000,000
Brabant Pharma Limited [Member] | Regulatory Milestones [Member]
Business Acquisition [Line Items]
Aggregate amount of contingent liabilities		50,000,000
Brabant Pharma Limited [Member] | Sales Milestones [Member]
Business Acquisition [Line Items]
Aggregate amount of contingent liabilities		$ 45,000,000
Notes Payable, Other Payables [Member]
Business Acquisition [Line Items]
Debt instrument, outstanding			$ 7,000,000
Sumavel DosePro [Member]
Business Acquisition [Line Items]
Proceeds from sale of business			85,000,000
Escrow deposit			8,500,000
Net product revenue			4,624,000
Sumavel DosePro [Member] | Notes Payable, Other Payables [Member]
Business Acquisition [Line Items]
Debt instrument, outstanding			7,000,000
Sumavel DosePro [Member] | Purchasing Entity [Member]
Business Acquisition [Line Items]
Contingent consideration, additional cash payments			$ 20,000,000